BIOS Capital Management, LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), BIOS Capital Management, LP reported 6 stock positions worth $79.2 million. Its top holding was Actuate Therapeutics (ACTU) at 84.6% of the portfolio, followed by Lantern Pharma (LTRN, 5.4%) and Rein Therapeutics (RNTX, 3.8%). Its holdings were unchanged from Q4 2024.
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $79.2M (Q1 2025)
- SEC Filing
- 0001104659-25-048606 ↗ filed May 14, 2025
Holdings Value
Holdings 6 stocks · $79.2M
| ACTU Actuate Therapeutics Inc. | 84.59% | 9,893,651 | $67.0M | No change |
| LTRN Lantern Pharma Inc. | 5.40% | 1,207,709 | $4.3M | No change |
| RNTX Rein Therapeutics Inc. | 3.78% | 1,690,751 | $3.0M | No change |
| CGTX Cognition Therapeutics Inc. | 3.19% | 6,000,000 | $2.5M | No change |
| INAB IN8BIO Inc. | 1.80% | 8,600,001 | $1.4M | No change |
| IRD Opus Genetics Inc. | 1.23% | 995,249 | $977K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |